Nokea
Immunosupressive effects of glucocorticoids are denominated with:
- A. Decrease of interleukins 1,2
- B. Activation of lymphocyte proliferation
- C. Increase amount of T lymphocytes
- D. Activation of lymphocyte transport at the site of antigen stimulation
Correct Answer: A
Rationale: Glucocorticoids suppress immunity by decreasing pro-inflammatory cytokines like interleukins 1 and 2.
You may also like to solve these questions
Tetracycline needs to be given on an empty stomach because it chelates with:
- A. Calcium
- B. Magnesium
- C. Iron
- D. All of the above
Correct Answer: D
Rationale: Tetracycline forms insoluble complexes with divalent and trivalent cations (calcium, magnesium, iron), reducing absorption when taken with food containing these elements.
Enterohepatic circulation is seen in
- A. Ampicillin
- B. Benzylpenicillin
- C. Norfloxacin
- D. Streptomycin
Correct Answer: D
Rationale: Streptomycin is excreted via bile and reabsorbed, unlike the others.
Drug of choice in motion sickness is
- A. Metoclopramide
- B. Transdermal scopalamine
- C. Diphenhydramine
- D. Chlorpromazine
Correct Answer: B
Rationale: Transdermal scopolamine is the drug of choice for motion sickness.
A nurse reviewing a client's medical record notes a new prescription for verifying the trough level of the client's medication. Which of the following actions should the nurse take?
- A. Obtain a blood specimen immediately prior to administering the next dose of medication.
- B. Verify that the client has been taking the medication for 24 hour before obtaining a blood specimen.
- C. Ask the client to provide a urine specimen after the next dose of medication.
- D. Administer the medication, and obtain a blood specimen 30 min late
Correct Answer: A
Rationale: Trough levels are measured just before the next dose to assess the lowest drug concentration in the blood.
Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to prescribing:
- A. Erythromycin
- B. Digoxin
- C. Cetuximab
- D. Rifampin
Correct Answer: C
Rationale: FDA requires pharmacogenetic testing for cetuximab to check EGFR status, not for erythromycin, digoxin, or rifampin.